Pregnancy outcomes associated with extended use of the 52-mg 20 μg/day levonorgestrel-releasing intrauterine system beyond 60 months: a chart review of 776 …

L Bahamondes, A Fernandes, MV Bahamondes… - Contraception, 2018 - Elsevier
Objective To assess the contraceptive performance of the 52-mg 20 μg/day levonorgestrel-
releasing intrauterine system (LNG-IUS, Mirena; Bayer Oy, Turku, Finland) among women …
被引用次数：33 相关文章

Pregnancy outcomes associated with extended use of the 52-mg 20 μg/day levonorgestrel-releasing intrauterine system beyond 60 months: A chart review of 776 …

L Bahamondes, A Fernandes, MV Bahamondes… - …, 2017 - europepmc.org
Objective To assess the contraceptive performance of the 52-mg 20 μg/day levonorgestrel-
releasing intrauterine system (LNG-IUS, Mirena; Bayer Oy, Turku, Finland) among women …

Pregnancy outcomes associated with extended use of the 52-mg 20 μg/day levonorgestrel-releasing intrauterine system beyond 60 months: A chart review of 776 …

L Bahamondes, A Fernandes… - …, 2018 - contraceptionjournal.org
Objective To assess the contraceptive performance of the 52-mg 20 μg/day levonorgestrel-
releasing intrauterine system (LNG-IUS, Mirena; Bayer Oy, Turku, Finland) among women …

Pregnancy outcomes associated with extended use of the 52-mg 20 μg/day levonorgestrel-releasing intrauterine system beyond 60 months: A chart review of 776 …

L Bahamondes, A Fernandes… - …, 2018 - pubmed.ncbi.nlm.nih.gov
Objective To assess the contraceptive performance of the 52-mg 20 μg/day levonorgestrel-
releasing intrauterine system (LNG-IUS, Mirena; Bayer Oy, Turku, Finland) among women …